Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 6

Results For "surgery"

295 News Found

Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care
News | December 16, 2024

Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care

Harnessing advanced data analysis for early detection, prevention and better outcomes


Health Minister Nadda inaugurates Medicine Update BJMFCON 2024
Policy | October 21, 2024

Health Minister Nadda inaugurates Medicine Update BJMFCON 2024

Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020


WHO declares India has eliminated Trachoma as a public health problem in 2024
Healthcare | October 10, 2024

WHO declares India has eliminated Trachoma as a public health problem in 2024

WHO estimates suggest that 150 million people worldwide are affected by Trachoma


Aster implements India’s first IOeRT for cancer care
Healthcare | October 09, 2024

Aster implements India’s first IOeRT for cancer care

To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients


Granules India launches 'Breast Health Express' mobile unit
Healthcare | September 26, 2024

Granules India launches 'Breast Health Express' mobile unit

The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need


Experts discuss on AI-driven solutions to improve healthcare
Digitisation | September 06, 2024

Experts discuss on AI-driven solutions to improve healthcare

Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare


Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer
Drug Approval | August 17, 2024

Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer

Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone